#Sustainability #China #Shanghai #Corporate Social Responsibility #WuXi Biologics

WuXi Biologics Achieves Recognition for Sustainability Efforts

WuXi Biologics, a prominent global player in the Contract Research, Development and Manufacturing Organization (CRDMO) sector, has once again affirmed its leadership in corporate sustainability by being featured in the S&P Global Sustainability Yearbook 2026. This marks the fourth consecutive year that the company has received such recognition, underscoring its unwavering commitment to enhancing sustainability practices within the industry.

The prestigious Yearbook recognizes companies that excel in social responsibility and sustainability, as established by their performance in the 2025 Corporate Sustainability Assessment (CSA). Out of more than 9,200 companies evaluated in the latest CSA, only 848 were honored for their exemplary efforts across 59 industries. WuXi Biologics distinguished itself by achieving a Top 1% score on the S&P Global CSA, earning it the highest level of acknowledgment available.

Dr. Chris Chen, the CEO of WuXi Biologics and chairman of the Environmental, Social and Governance (ESG) Committee, voiced pride in the company's achievements. He noted, "Our achievements in the S&P Global CSA and our inclusion in the Yearbook for the fourth consecutive year clearly demonstrate our ongoing dedication to improving our sustainability performance. As a global leader in Green CRDMO, we consistently strive for excellence in ESG, helping our partners meet their commitments and working collaboratively with all stakeholders to endorse responsible practices throughout our value chain."

WuXi Biologics stands as a proactive advocate for sustainability. The company is a participant in significant initiatives such as the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI). Their commitment has garnered numerous accolades, including an MSCI AAA Rating, an EcoVadis Platinum Medal, and distinct placements in the Dow Jones Sustainability Indices (DJSI). Additionally, they have made the CDP 'A List' for Climate Change, Water Security, and Supplier Engagement Assessment while being recognized as a top-rated ESG company by Sustainalytics for five straight years.

These recognitions are a testament to WuXi Biologics' unwavering focus on sustainability. The company’s commitment is fully integrated into its core business strategy, with the aim of becoming a leading force in ESG within the CRDMO sector. Their state-of-the-art facilities utilize advanced biomanufacturing technologies and are powered by clean energy sources to align with their sustainability objectives.

As of the end of 2025, WuXi Biologics reported supporting 945 integrated client projects, of which 74 were in Phase III clinical trials and 25 in commercial manufacturing. This remarkable scope underscores the company's role in advancing healthcare while adhering to robust environmental and social governance principles.

WuXi Biologics aims to continue this trajectory of excellence and innovation, fostering efforts to meet the increasing demand for sustainable practices in the biologics industry. Their comprehensive ESG strategy, spearheaded by a dedicated committee led by the CEO, exemplifies their commitment to steering impactful social and environmental change across all platforms.

For those interested in learning more about their sustainability initiatives and overall business offerings, WuXi Biologics invites further exploration of their practices and achievements at wuxibiologics.com.